Terremoto Biosciences raised $108 million in a Series C to develop small-molecule medicines targeting AKT, funding further first-in-human progress for oral candidates. New investors include RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines, with existing backers also participating. The company said its lead program, TER-2013, is in Phase 1 for solid tumors with specific genetic alterations, and TER-4480 is expected to enter the clinic for hereditary hemorrhagic telangiectasia (HHT), where the company noted no approved therapies exist. The financing comes as other AKT efforts have shown mixed late-stage outcomes across the class. Terremoto’s focus on “covalency technologies” suggests it intends to differentiate on durability and safety while building a pipeline in both oncology and rare bleeding disorders.